Trials
3 active
12 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Prostate Cancer (2 trials), Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Main trialPhase 3
- “This study aims to compare the efficacy and safety of rezvilutamide with enzalutamide in the treatment of patients with low-volume metastatic hormone sensitive prostate cancer.”In the company’s words, NCT07241416 on ClinicalTrials.gov
- Other names
- SHR3680
Other drugs for Prostate Cancer
- ApalutamideJohnson & Johnson (Janssen) · Phase 3
- 64Cu-SAR-bisPSMAClarity Pharmaceuticals Ltd · Phase 3
- Abiraterone acetateJohnson & Johnson (Janssen) · Phase 3
- 68Ga-PSMA-11Telix Pharmaceuticals (Innovations) Pty Limited · Phase 3
- EnzalutamidePfizer · Astellas · Phase 3
- MevrometostatPfizer · Phase 3
Coming up3
- Mar 2027Phase 3 trial completes · ClinicalTrials.gov
- Nov 2027Phase 1/2 trial completes · ClinicalTrials.gov
- Dec 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials12
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Mar 2027 | A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer | |
| Phase 2Recruiting | Dec 2028 | A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer | |
| Phase 1/2Recruiting | Nov 2027 | A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer | |
| Phase 3Unknown | 30 Apr 2023 | A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer | |
| Phase 3Terminated | 6 Sep 2024 | A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy | |
| Phase 2Terminated | 31 Aug 2021 | A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC | |
| Phase 2Unknown | 1 Oct 2022 | A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPC | |
| Phase 1/2Terminated | 30 Sep 2019 | A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC | |
| Phase 1Unknown | 15 Mar 2021 | Relative Bioavailability Study of SHR3680 | |
| Phase 1Completed | 8 Sep 2021 | Drug-durg Interaction of SHR3680 With Digoxin, Rosuvastatin Calcium and Metformin Hydrochloride | |
| Phase 1Unknown | Jul 2023 | An Investigational Study of SHR3680 in Participants With Mild to Moderate Liver Impairment and Healthy Participants | |
| Phase 1Unknown | 5 Nov 2024 | A SHR3680 QT/QTc Study on Castration-Resistant Prostate Cancer Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026